Clinical Trials Directory

Trials / Completed

CompletedNCT05994092

Influence of Voluntary Isocapnic Hyperpnea on Blood Lactate Level and Rate of Perceived Exertion

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
39 (actual)
Sponsor
Institute of Sport - National Research Institute, Poland · Academic / Other
Sex
All
Age
Healthy volunteers
Accepted

Summary

All the study participants performed the Wingate Anaerobic Test (WAnT) with maximal effort. The experimental group (E) performed a 3-minute recovery protocol based on low-intensity breathing Voluntary Isocapnic Hyperpnea exercises 20 minuter after cessation of the exercise, whereas the control group (C) used passive recovery only. All study participants were advised to sit during the 30-minute period, with minimal walking in order to meet the physiological needs allowed. The blood samples were taken 3 minutes and 30 minutes after cessation of the exercise to measure the bLa. The Borg CR-10 Scale was presented to the participants 3 minutes and 30 minutes after cessation of the exercise to measure the rate of perceived exertion (RPE) (Borg, 1998).

Detailed description

All the study participants performed the Wingate Anaerobic Test (WAnT) with maximal effort. The experimental group (E) performed a 3-minute recovery protocol based on low-intensity breathing VIH exercises 20 minuter after cessation of the exercise, whereas the control group (C) used passive recovery only. All study participants were advised to sit during the 30-minute period, with minimal walking in order to meet the physiological needs allowed. The blood samples were taken 3 minutes and 30 minutes after cessation of the exercise to measure the bLa. The Borg CR-10 Scale was presented to the participants 3 minutes and 30 minutes after cessation of the exercise to measure the rate of perceived exertion (RPE). WAnT was conducted using a Monark 874E Cycle Ergometer (Monark Exercise AB, Sweden). Prior to the test, a standard warm-up of 5 minutes was performed with a load of 0.8-1.2 W/kg. Then, athletes performed a maximal 6-second sprint with a load adjusted to 7.5% of the individual body weight. Following a 2-minute rest period, the athletes underwent a 30-second WAnT with the load adjusted to 7.5% of the individual body weight. The objective for the subjects was to achieve the highest possible peak power as fast as possible and maintain the highest power output throughout the whole test duration. Loud and dynamic verbal encouragement was provided. The testing took place between 9:00 and 10:30 AM. The basic mechanical parameters of the exercise, including performed work and maximum power, were computed with dedicated software (MCE 6.0 - JBA Z. Staniak, Poland) linked to the cycle ergometer. The recovery protocol consisted of 3' of breathing with 20 breaths·min-1 frequency. The Isocapnic BreathWayBetter devices (Isocapnic Technologies Inc, Kelowna, Canada) with 6-liter bags were used. The protocol was performed in a seating position. Blood samples were taken from fingertips by skilled technicians to 20 uL capillary tubes. bLa was measured with Super GL2 analyzer (Dr. Müller Gerätebau GmbH, Freital, Germany). Whereas participants and data collectors were aware of the allocated training method, the laboratory technicians performing biochemistry assays were kept blinded to the allocation. The participants were assigned at random to either E or C group to perform VIH protocol under a supervision of qualified physiotherapist. Stratified randomization to assign the participants was used. First, the participants were assigned to subgroups based on the membership in National Development or National Elite Team. Then, the participants were assigned to subgroups based on the gender. Then, the participants were assigned to E or C group based on the coin toss.

Conditions

Interventions

TypeNameDescription
BEHAVIORALVoluntary Isocapnic HyperpneaThe protocol of 3' of breathing with 20 breaths·min-1 frequency. The Isocapnic BreathWayBetter devices (Isocapnic Technologies Inc, Kelowna, Canada) with 6-liter bags were used. The protocol was performed in a seating position.

Timeline

Start date
2023-06-10
Primary completion
2023-07-30
Completion
2023-07-30
First posted
2023-08-16
Last updated
2023-08-18

Locations

1 site across 1 country: Poland

Source: ClinicalTrials.gov record NCT05994092. Inclusion in this directory is not an endorsement.